| 摘要 |
<p>The present invention is directed to a polynucleotide of less than about 50 nucleic acid bases in length, which polynucleotide hybridizes to the tenascin gene. The present invention is also directed to a pharmaceutical composition comprising the above polynucleotide dissolved or dispersed in a physiologically tolerable diluent. The present invention is further directed to a process for inhibiting vascular smooth muscle cell proliferation which process comprises inhibiting the expression of tenascin in vascular smooth muscle cells.</p> |
